|
시장보고서
상품코드
1563123
세계의 눈 알레르기 치료제 시장 : 유형, 약제 클래스, 치료 형태, 유통 채널, 지역별 예측(-2032년)Global Eye Allergy Treatment Market Research Report Information By Type, By Drug Class, By Treatment Form, By Distribution Channel And By Region Forecast to 2032 |
||||||
눈 알레르기 치료제 시장 규모는 2023년 33억 5,000만 달러, 2024년 35억 5,000만 달러에서 예측 기간 동안 6.23%의 복합 연간 성장률(CAGR)로 성장을 지속하여 2032년에는 56억 2,000만 달러 규모로 성장할 것으로 예상됩니다. 눈알레르기 유병률 상승, 노령 인구 확대, 높은 수요를 충족하는 의약품상시 증가 등이 시장 성장의 원동력이 되고 있습니다.
세계에서 눈 알레르기가 증가하고 있는 것이 이 시장의 확대를 뒷받침하고 있습니다. 예를 들어, Alcon은 2020년 2월에 약 6,600만 명의 미국인이 눈 알레르기를 가지고 있다고 추정합니다. 또한 노인 인구 증가도 시장을 견인하고 있습니다. Senior Home Plus에 따르면 노인의 눈 알레르기는 면역 체계 감소, 만성 건강 문제, 눈물 분비량 감소, 일부 약물의 부작용 등으로 인해 발생합니다.
지역별 인사이트력
북미는 2023년에 가장 큰 시장 점유율을 보였습니다. 시장 규모는 예측 기간 동안 4.29%의 복합 연간 성장률(CAGR)로 성장을 지속하여 2032년에는 19억 4,000만 달러의 규모에 이를 것으로 예측되고 있습니다. 반면 아시아태평양은 예측 기간 동안 최대 복합 연간 성장률(CAGR) 7.11%로 성장할 것으로 예측됩니다.
유럽은 두 번째 시장 점유율을 차지합니다. 그 이유는 안과 질환 환자 증가, 고급 치료 시설의 가용성, 의료비 증가, 고급 치료법의 도입, 강력한 의료 인프라의 존재 등입니다. 또한 정부의 이니셔티브이 활발해지고 있는 것도 시장 확대에 박차를 가하고 있습니다. 또한, 노인 인구 증가도 같은 시장을 견인하고 있습니다.
아시아태평양은 급성장 지역입니다. 환자 인구의 많음, 신속한 기술의 진보, 시장의 발전의 전망 등이 이 지역 시장 성장에 기여하고 있습니다. 또한 노인 인구 증가도 시장을 견인하고 있습니다.
이 보고서는 세계의 눈 알레르기 치료제 시장을 조사했으며,, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이, 예측, 각종 구분, 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 눈알레르기의 이환율의 상승과 노인 인구 증가
- 수요 증가에 부응하기 위한 신약 발매 급증
- 억제요인
- 결막염과 관련된 인식의 부족
- 기회
- 진행중인 임상시험
제5장 시장 요인 분석
- Porter's Five Forces 분석
- COVID-19가 세계의 눈 알레르기 치료제 시장에 미치는 영향
제6장 세계의 눈 알레르기 치료제 시장 : 유형별
- 개요
- 계절성 및 연중 알레르기 성 결막염
- 춘계 카탈
- 아토피성 각결막염
- 접촉성 알레르기성 결막염
- 거대 유두 결막염
제7장 세계의 눈 알레르기 치료제 시장 : 약제 클래스별
- 개요
- 항히스타민제
- 마스트 세포 안정제
- 비스테로이드성 항염증제
- 코르티코스테로이드
- 충혈 제거제
- 면역요법 알레르기 주사
- 피하 면역 요법 알레르기 주사 치료(SCIT)
- 설하 면역 요법 알레르기 주사 치료(SLIT)
- 기타
제8장 세계의 눈 알레르기 치료제 시장 : 형태별
- 개요
- 점안약
- 주사제
- 정제,캡슐
제9장 세계의 눈 알레르기 치료제 시장 : 유통 채널별
- 개요
- 병원 약국
- 온라인 약국
- 소매 약국
제10장 세계의 눈 알레르기 치료제 시장 :지역별
- 세계의
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제11장 경쟁 구도
- 시장 점유율 분석
- 경쟁 대시보드
- 공개 기업의 주식 개요
- 비교 분석 : 주요 기업의 재무 동향
- 주요 전개와 성장 전략
제12장 기업 프로파일
- JOHNSON & JOHNSON SERVICES, INC
- ABBVIE INC.
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- HAL ALLERGY BV
- NOVARTIS AG
- BAUSCH LOMB
- SANTEN PHARMACEUTICAL CO., LTD.
- ALCON
- BAYER AG
Global Eye Allergy Treatment Market Research Report Information By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, Giant Papillary Conjunctivitis), By Drug Class (Antihistamine, Mast Cell Stabilizer, NASAIDs, Corticosteroid, Decongestants, Immunotherapy Allergy Shots, Others), By Treatment Form (Eyedrops, Injectables, Tablets & Capsules), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies) And By Region Forecast to 2032
Market Overview
In 2023, the market for eye allergy treatments was estimated to be worth USD 3.35 billion. The market is expected to expand from USD 3.55 billion in 2024 to USD 5.62 billion by 2032, representing a compound annual growth rate (CAGR) of 6.23% over the forecast period (2024-2032). The rising prevalence of ocular allergies, an expanding geriatric population, and increased medicine launches to fulfill high demand are driving market expansion.
The growing frequency of eye allergies around the world is driving the expansion of the Eye Allergy Treatment Market. For example, in February 2020, Alcon, a Novartis AG (US) firm, estimated that approximately 66 million Americans have ocular allergies. Furthermore, the growing senior population is driving the eye allergy treatment market. According to Senior Home Plus (UK), eye allergies in the older population are caused by a compromised immune system, chronic health issues, decreased tear production, and some drug adverse effects. The market is poised for tremendous development. For example, according to the World Population Prospects 2022, the population above the age of 65 is expanding faster than the population below that age. Furthermore, it has been anticipated that the share of the global population aged 65 and up will increase from 10% in 2022 to 16% by 2050. Furthermore, the growing senior population in Asia-Pacific will provide profitable growth prospects in the coming years. According to the Asia-Pacific Report on Population Ageing 2022, Asia-Pacific had roughly 670 million persons aged 60 and up in 2022. Thus, the increasing prevalence of eye allergies, as well as the growing senior population, are driving global market expansion.
Market Segment insights
The Eye Allergy Treatment Market is divided into five types: seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis.
The Eye Allergy Treatment Market is divided into pharmacological classes, including antihistamines, mast cell stabilizers, NSAIDS, corticosteroids, decongestants, immunotherapy allergy shots, and others.
The Eye Allergy Treatment Market is divided into three segments based on treatment form: eyedrops, injectables, and tablets/capsules.
The Eye Allergy Treatment Market is divided into three distribution channels: hospital pharmacies, internet pharmacies, and retail pharmacies.
Regional insights
The Eye Allergy Treatment Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America had the biggest market share in 2023 and is expected to reach USD 1.94 billion by 2032, representing a CAGR of 4.29% over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 7.11% over the projection period.
The Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share due to an increasing patient population with eye disorders, the availability of advanced treatment facilities, rising healthcare expenditure, the introduction of advanced therapies into the market, and the presence of a strong healthcare infrastructure. In addition, increased government initiatives are fueling market expansion. Furthermore, the growing senior population is driving the eye allergy treatment market.
Asia-Pacific is the fastest-growing region for Eye Allergy Treatment Market. The presence of a large patient population, quick technological advancement, and numerous prospects for market development all contribute to the growth of the Asia-Pacific eye allergy treatment market. Furthermore, the growing geriatric population is driving the market for eye allergy treatments in this region.
Major Players
Major participants in the Eye Allergy Treatment Market include Johnson & Johnson Services, Inc., Abbvie Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Hal Allergy B.V., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Alcon, and Bayer AG.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
- 3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
- 3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
- 3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
- 4.1 INTRODUCTION
- 4.2 DRIVERS
- 4.2.1 RISING PREVALENCE OF EYE ALLERGY AND EXPANDING GERIATRIC POPULATION
- 4.2.2 SURGING DRUG LAUNCHES IN ORDER TO MEET HIGH DEMAND
- 4.3 RESTRAINTS
- 4.3.1 LACK OF AWARENESS ASSOCIATED WITH CONJUNCTIVITIS
- 4.4 OPPORTUNITY
- 4.4.1 ONGOING CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
- 5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
- 5.2 IMPACT OF COVID-19 ON THE GLOBAL EYE ALLERGY TREATMENT MARKET
6 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TYPE
- 6.1 OVERVIEW
- 6.2 SEASONAL AND PERENNIAL ALLERGIC CONJUNCTIVITIS
- 6.3 VERNAL KERATOCONJUNCTIVITIS
- 6.4 ATOPIC KERATOCONJUNCTIVITIS
- 6.5 CONTACT ALLERGIC CONJUNCTIVITIS
- 6.6 GIANT PAPILLARY CONJUNCTIVITIS
7 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS
- 7.1 OVERVIEW
- 7.2 ANTIHISTAMINE
- 7.3 MAST CELL STABILIZER
- 7.4 NSAIDS
- 7.5 CORTICOSTEROID
- 7.6 DECONGESTANTS
- 7.7 IMMUNOTHERAPY ALLERGY SHOTS
- 7.7.1 SUBCUTANEOUS IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SCIT)
- 7.7.2 SUBLINGUAL IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SLIT)
- 7.8 OTHERS
8 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM
- 8.1 OVERVIEW
- 8.2 EYEDROPS
- 8.3 INJECTABLES
- 8.4 TABLETS & CAPSULES
9 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 9.1 OVERVIEW
- 9.2 HOSPITAL PHARMACIES
- 9.3 ONLINE PHARMACY
- 9.4 RETAIL PHARMACY
10 GLOBAL EYE ALLERGY TREATMENT MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
- 10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
- 10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
- 10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 MARKET SHARE ANALYSIS,
- 11.3 COMPETITOR DASHBOARD
- 11.4 PUBLIC PLAYERS STOCK SUMMARY
- 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
12 COMPANY PROFILES
- 12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 ABBVIE INC.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGY
- 12.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
- 12.5 HAL ALLERGY B.V.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
- 12.6 NOVARTIS AG
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
- 12.7 BAUSCH + LOMB
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
- 12.8 SANTEN PHARMACEUTICAL CO., LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
- 12.9 ALCON
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
- 12.10 BAYER AG
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES
